Sengenics, Parkway Partner on Genetic Testing in Singapore | GenomeWeb

NEW YORK (GenomeWeb News) – Sengenics and Parkway Laboratory Services have entered into a partnership to offer genetics tests in Singapore, Sengenics said on Thursday.

The deal focuses on Sengenics' CardioSure heart disease test and Sequenom's MaterniT21 Plus non-invasive prenatal diagnostic test. The CardioSure test, Sengenics said, is based on a concept of "Asianized Diagnostics" to include disease biomarkers from Asian ethnic groups as well as those from Caucasian and African populations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.